美迪西诞愿有您！

2021年转眼即将到尾声了

感谢大家陪我们又走过了一年的春夏秋冬

也希望在未来日子里

能一直与您相伴~

01

In 2021, more than 70 projects that Medicilon participated in successfully passed clinical trials.

2021年美迪西与客户合作成功获得临床批准的项目超过70件。

02

Medicilon currently has more than 2,000 scientists and supporting staffs, with 3 R&D centers and a lab space of more than 70,000 square meters.

美迪西现有2000多名员工，3个研发中心，实验室面积超过70000平方米。

03

We are committed to enhancing our global service and customer experience with our U.S. Office and European office!

美迪西在北美洲和欧洲等地都有服务网络覆盖！致力于增强全球化服务和客户体验！

04

We have won a number of heavyweight awards such as "Top 50 Growth Listed Companies", "Top Chinese R&D CRO Enterprises in 2021", “Golden Horse Award-2021 Best Preclinical CRO/CDMO Enterprise”, etc.

荣获多项重量级奖项——“上市公司成长性50强”、“2021中国研发CRO企业20强”、“金马奖—2021最佳临床前CRO/CDMO企业”等。

05

We have established some new service platforms such as PROTAC Drug Discovery Research Platform, Solid Form Screening Platform by Process Department, mRNA Vaccine Bioanalysis Platform, Preclinical Ophthalmic Research Platform, et al.

建立了PROTAC药物发现研究平台、工艺部固体形式筛选平台、mRNA疫苗生物分析平台、临床前眼科研究平台等多个新型服务平台。

06

We have organized several seminars in different cities in China. In addition, we have also exhibited in several worldwide professional academic conferences, such as AACR, DOT, ELRIG, AAPS, etc.

我们在国内多个城市组织多次美迪西专题研讨会；也参加了多个海外专业学术会议，如AACR, DOT, ELRIG, AAPS等。

春去冬来，日新月异。

走过 2021！迎来 2022！

美迪西感谢您的支持和信任！

美迪西为您准备了精美的小礼品。